Revance Therapeutics Appoints New Chief Revenue Officer to Enhance Growth in Aesthetics and Therapeutics
- Revance Therapeutics appoints Steve Kreider as Chief Revenue Officer to enhance U.S. sales in aesthetics and therapeutics.
- Kreider brings over 20 years of experience, aiming to drive growth and implement effective sales strategies.
- Revance focuses on innovation and adapting to market demands, aiming for sustainable growth in aesthetics and skincare.
Revance Therapeutics Welcomes New Chief Revenue Officer to Drive Growth in Aesthetics and Therapeutics
Revance Therapeutics, a prominent player in the aesthetics and skincare sector, announces the appointment of Steve Kreider as Executive Vice President and Chief Revenue Officer for Aesthetics and Therapeutics. This strategic move comes at a time when the company seeks to bolster its commercial strategies in the U.S. market, which has become increasingly competitive. Kreider steps into this newly established role with the objective of enhancing Revance's sales operations and revenue generation across both its aesthetic and therapeutic divisions.
Kreider brings over two decades of experience in commercial leadership within the aesthetics and therapeutics fields, a background that positions him well to navigate the challenges and opportunities present in these fast-evolving markets. Previously, he held a senior leadership position at Cutera and has been instrumental in driving brand transformations and successful product launches at major companies, including Ortho Dermatologics, Merz Aesthetics, and Medicis. His wealth of experience is expected to be pivotal in implementing effective sales and marketing strategies that align with Revance's innovative product offerings, including its flagship DAXXIFY® and the RHA® Collection of dermal fillers.
CEO Nadeem Moiz expresses strong confidence in Kreider's ability to amplify Revance's market presence and commercial execution. With Kreider at the helm of U.S. sales efforts, Revance aims to accelerate growth across its diverse portfolio, which spans 60 countries. The company is committed to continuously adapting to the changing demands of consumers and healthcare providers, ensuring that it remains at the forefront of innovation in aesthetics and skincare. Kreider’s leadership is expected to unlock the long-term potential of Revance as it strives for sustainable growth in a dynamic industry.
In addition to Kreider's appointment, Revance continues to focus on its mission of delivering cutting-edge solutions in aesthetics and therapeutics. The company’s commitment to innovation is evident in its range of products designed to meet the needs of both consumers and healthcare professionals. As Revance positions itself for future growth, the expectation is that its strategic initiatives will not only fortify its market leadership but also enhance the overall patient experience in aesthetic care.
With the strategic hiring of a seasoned executive like Kreider, Revance Therapeutics is well-equipped to tackle the challenges of a competitive landscape while delivering high-quality, innovative products that meet the evolving needs of its clients.